

Substitute for form 1449/PTO
(Revised 07/2005)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/780,296
Filing Date	February 17, 2004
First Named Inventor	Wilson
Group Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	049542/283879

Sheet 1 of 4

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MB	3	US-2,887,486	05-19-1959	Leake <i>et al.</i>	
	4	US-3,031,451	04-24-1962	Schlesinger <i>et al.</i>	
	5	US-3,309,271	03-14-1967	Georges <i>et al.</i>	
	6	US-3,317,533	05-02-1967	De Ridder	
	7	US-3,961,060	06-01-1976	Fuxe	
	8	US-4,092,417	05-30-1978	Credner <i>et al.</i>	
	9	US-4,299,832	11-10-1981	Brown <i>et al.</i>	
	10	US-4,378,359	03-29-1983	Chiodoni <i>et al.</i>	
	11	US-4,548,818	10-22-1985	Kjellin <i>et al.</i>	
	12	US-4,612,315	09-16-1986	Jacobson <i>et al.</i>	
	13	US-4,622,324	11-11-1986	Klessing <i>et al.</i>	
	14	US-4,696,932	09-29-1987	Jacobson <i>et al.</i>	
	15	US-4,769,377	09-06-1988	Snyder <i>et al.</i>	
	16	US-4,772,607	09-20-1988	Badger <i>et al.</i>	
	17	US-4,868,186	09-19-1989	Franzone <i>et al.</i>	
	18	US-4,968,672	11-06-1990	Jacobson <i>et al.</i>	
	19	US-4,971,972	11-20-1990	Doll <i>et al.</i>	
	20	US-5,032,593	07-16-1991	Rzeszutarski <i>et al.</i>	
	21	US-5,066,655	11-19-1991	Olsson	
	22	US-5,068,236	11-26-1991	Suzuki <i>et al.</i>	
	23	US-5,208,240	05-04-1993	Peet <i>et al.</i>	
	24	US-5,248,770	09-28-1993	Jacobson <i>et al.</i>	
	25	US-5,256,650	10-26-1993	Peet <i>et al.</i>	
	26	US-5,296,463	03-22-1994	Lee <i>et al.</i>	
MB	27	US-5,298,508	03-29-1994	Jacobson <i>et al.</i>	

Examiner Signature	/Mark L. Berch/	Date Considered	07/13/2006
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/780,296
				Filing Date	February 17, 2004
				First Named Inventor	Wilson
				Group Art Unit	1614
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	049542/283879

U. S. PATENT DOCUMENTS					
MB	28	US-5,314,890	05-24-1994	Agostini <i>et al.</i>	
	29	US-5,340-813	08-23-1994	Klein <i>et al.</i>	
	30	US-5,395,836	03-07-1995	Shimada <i>et al.</i>	
	31	US-5,434,150	07-18-1995	Austel <i>et al.</i>	
	32	US-5,447,933	09-05-1995	Suzuki <i>et al.</i>	
	33	US-5,532,368	07-02-1996	Kufner-Muhl <i>et al.</i>	
	34	US-5,543,415	08-06-1996	Suzuki <i>et al.</i>	
	35	US-5,545,627	08-13-1996	Jacobson <i>et al.</i>	
	36	US-2002/0082269 A1	06-27-2002	Neely	
	37	US-2004/0014766 A1	01-22-2004	Dunten <i>et al.</i>	
MB	38	US-2005/0187226 A1	08-25-2005	Wilson <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
MB	39	BE 636 828 A	03-02-1964	MR A.H.E. GEORGES		
	40	GB 947,495	01-22-1964	RIDDER		
	41	DE 1 245 383	07-27-1967	DE RIDDER		
	42	DE 26 59 241	07-06-1978	KLOSA		
	43	EP 0 501 379 A2	09-02-1992	KYOWA HAKKO KOGYO CO., LTD.		
	44	EP 0 503 563 A2	09-16-1992	MERRELL DOW PHARMACEUTICALS INC.		
	45	EP 0 764 647 A1	03-26-1997	BAYER AG		
	46	FR 2 483 922	11-12-1981	DE RIDDER		
	47	WO 2003/028730 A2	04-10-2003	NORVATIS AG		
MB	48	WO 2004/074247 A2	09-02-2004	ENDACEA, INC		
Examiner Signature	/Mark L. Berch/			Date Considered	07/13/2006	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/780,296
				Filing Date	February 17, 2004
				First Named Inventor	Wilson
				Group Art Unit	1614
				Examiner Name	To Be Assigned
Sheet	3	of	4	Attorney Docket Number	049542/283879

FOREIGN PATENT DOCUMENTS						
MB	49	WO 2004/110379 A2	12-23-2004	ENDACEA, INC		

OTHER DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		English Language Translation Attached
MB	50	ABBRACCHIO, M.P. and F. CATTABENI, "Selective Activity of Bamifylline on Adenosine A ₁ -Receptors in Rat Brain," <i>Pharmacological Research Communications</i> , 1987, pp. 537-545, Vol. 19(8).		
	51	BELLARDO, F. and C. LUCARELLI, "Micro-Scale Liquid Chromatographic Method for the Determination of Bamifylline and its Major Metabolite in Human Plasma," <i>Journal of Chromatography</i> , 1990, pp. 305-309, Vol. 535.		
	52	CARLUCCI, G., <i>et al.</i> , "Determination of Bamifylline Hydrochloride Impurities in Bulk Material and Pharmaceutical Forms Using Liquid Chromatography with Ultraviolet Detection," <i>Journal of Pharmaceutical & Biomedical Analysis</i> , 1990, pp. 1067-1069, Vol. 8.		
	53	JACOBSON, K.A., <i>et al.</i> , "A Functionalized Congener Approach to Adenosine Receptor Antagonists: Amino Acid Conjugates of 1,3-Dipropylxanthine," <i>Molecular Pharmacology</i> , 1985, pp. 126-133, Vol. 29.		
	54	JACOBSON, K.A., <i>et al.</i> , "Electrophilic Derivatives of Purines as Irreversible Inhibitors of A ₁ Adenosine Receptors," <i>Journal of Medicinal Chemistry</i> , 1989, pp. 1043-1051, Vol. 32.		
	55	JACOBSON, K.A., <i>et al.</i> , "Molecular Probes for Extracellular Adenosine Receptors," <i>Biochemical Pharmacology</i> , 1987, pp. 1697-1707, Vol. 36(10).		
	56	MÜELLER, C.E., <i>et al.</i> , "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A ₁ Selective Adenosine Receptor Antagonists," 1990, pp. 2822-2828, Vol. 33(10).		
	57	NEELY, C.F., <i>et al.</i> , "A ₁ Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart," <i>AHA-Circulation</i> , November 1996, pp. 1-5, 94(9).		
	58	PATEL, A. <i>et al.</i> , "I-BW-A844U, an Antagonist Radioligand with High Affinity and Selectivity for Adenosine A ₁ Receptors, and ¹²⁵ I-Azido-BW-A844U, a Photoaffinity Label," <i>Molecular Pharmacology</i> , 1988, pp. 585-591, Vol. 33.		
MB	59	POULSEN, S-A and R.J. Quinn, "Adenosine Receptors: New Opportunities for Future Drugs," <i>Bioorganic & Medicinal Chemistry</i> , 1998, pp. 619-641, Vol. 6.		

Examiner Signature	/Mark L. Berch/	Date Considered	07/13/2006
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/780,296
				Filing Date	February 17, 2004
				First Named Inventor	Wilson
				Group Art Unit	1614
				Examiner Name	To Be Assigned
Sheet	4	of	4	Attorney Docket Number	049542/283879

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
MB	60	SCHIANTARELLI, P., <i>et al.</i> , "Evidence of Pulmonary Tropism of Bamifylline and its Main Active Metabolite," <i>Arzneim.-Forsch/Drug Res.</i> , 1989, pp. 215-219, Vol. 39.	
MB	61	VAN GALEN, P.J.M., "Adenosine A ₁ and A ₂ Receptors: Structure-Function Relationships," <i>Medicinal Research Reviews</i> , 1992, pp. 423-471, Vol. 12.	
MB	62	VAN RHEE, A.M., <i>et al.</i> , "Tetrahydrobenzothiophenone Derivatives as a Novel Class of Adenosine Receptor antagonists," <i>J. Med. Chem.</i> , 1996, pp. 398-406, Vol. 39(2).	
MB	63	WINDHOLZ, M., ed., "Bamethan," <i>The Merck Index</i> , 1983, p. 138, Tenth Edition, Merck & Co., Inc., Rahway, N.J.	
MB	64	"Communications to the Editor," <i>J. Med. Chem.</i> , 1992, pp. 3578-3581, Vol. 35(19).	
MB	65	"Other News to Note," <i>BioWorld Today</i> , March 1996, p. 2.	

RTA01/2194749v1

Examiner Signature	/Mark L. Berch/	Date Considered	07/13/2006
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO
(Revised 07/2005)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

FEB 23 2006

OFFICE OF
THE
PATENT
AND
TRADEMARK
OFFICE

Complete if Known

Application Number	10/780,296
Filing Date	February 17, 2004
First Named Inventor	Wilson
Group Art Unit	1624
Examiner Name	M. Berch
Attorney Docket Number	049542/283879

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MB	66	US-2,840,559	06-24-1958	KRANTZ, J.C. <i>et al.</i>	
MB	67	US-5,290,782	03-01-1994	SUZUKI, F. <i>et al.</i>	
MB	68	US-5,714,494	02-03-1998	CONNELL <i>et al.</i>	
MB	69	US-5,739,331	04-14-1998	THYRION <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached


RTA01/2199334v1

Examiner Signature	/Mark L. Berch/	Date Considered	07/13/2006
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO
(Revised 07/2005)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Sheet	1	of	3	Attorney Docket Number	049542/283879
-------	---	----	---	------------------------	---------------

Complete if Known

Application Number	10/780,296
Filing Date	February 17, 2004
First Named Inventor	Wilson
Group Art Unit	1624
Examiner Name	M. Berch

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MB	1	4,879,296	11-07-1989	Daluge et al.	
	2	5,290,782	3-01-1994	Suzuki et al.	
	3	5,504,090	4-02-1996	Neely, C.F.	
	4	5,733,916	3-31-1998	Neely, C.F.	
	5	5,932,557	8-03-1999	Mustafa et al.	
	6	6,001,842	12-14-1999	Neely, C.F.	
	7	6,117,445	9-12-2000	Neely, C.F.	
	8	2002/0111333 A1	8-15-2002	Lin et al	
	9	2003/0212082 A1	11-13-2003	Linden et al.	
MB	10	2004/0110774 A1	6-10-2004	Wilson, C.N.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
MB	11	JP 9216883A	8-19-1997	Kuroda et al.		Abstract only
MB	12	WO 98/03507	1-29-1998	Akahane et al.		
MB	13	WO 99/67239 A1	12-29-1999	Akahane et al.		
MB	14	WO 01/34610 A1	5-17-2001	Kiesman et al.		
MB	15	WO 03/028730 A2	10-04-2003	Novartis AG		

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
MB	16	ALI, et al., "Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A ₁ Receptor," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 1993, pp. 1328-1334, Vol. 268(3).	
MB	17	ANGULO, et al., "A ₁ Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation," <i>Brain Pathol.</i> 2003, -pp. 440-451.	

Examiner Signature	/Mark L. Berch	Date Considered	07/13/2006
--------------------	----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/780,296
				Filing Date	February 17, 2004
				First Named Inventor	Wilson
				Group Art Unit	1624
Examiner Name	M. Berch				
Sheet	2	of	3	Attorney Docket Number	049542/283879

U. S. PATENT DOCUMENTS					
MB	18	ASLANIAN, <i>et al.</i> , "Cardiovascular and Pulmonary Diseases," <i>Annual Reports in Medicinal Chemistry</i> , 2001, pp. 32-40, Vol. 36(II), Academic Press, San Diego, CA.			
	19	BALL, <i>et al.</i> , "Clinical Potential of Respirable Antisense Oligonucleotides (RASONS) in Asthma," <i>Am. J. Pharmacogenomics</i> , 2003, pp. 97-106, Vol. 3(2).			
	20	BERTI, <i>et al.</i> , "Pharmacological Activity of Bamifylline on Lung Anaphylaxis: <i>In Vitro</i> Studies," <i>Pharmacological Research</i> , 1990, Vol. 22(2).			
	21	CRONSTEIN, <i>et al.</i> , "Neutrophil Adherence to Endothelium is "Enhanced Via Adenosine A ₁ Receptors and Inhibited Via Adenosine A ₂ Receptors," <i>The Journal of Immunology</i> , 1992, pp. 2201-2206, Vol. 148.			
	22	CRONSTEIN, <i>et al.</i> , "The Adenosine/Neutrophil Paradox Resolved: Human Neutrophils Possess Both A ₁ and A ₂ Receptors that Promote Chemotaxis and Inhibit O ₂ Generation, Respectively," <i>J. Clin. Invest.</i> , 1990, pp. 1150-1157, Vol. 85.			
	23	DAR, M.S. <i>et al.</i> , "Acute Ethanol / Cannabinoid-Induced Ataxia and Its Antagonism by Oral/Systemic/Intracerebellar A ₁ Adenosine Receptor Antisense in Mice," <i>Brain Research</i> , 2002, pp. 53-60, Vol. 957.			
	24	FORMAN, <i>et al.</i> , "Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemoattractant Response," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 2000, pp. 929-938, Vol. 292(3).			
	25	GASPARDONE, <i>et al.</i> , "Bamiphylline Improves Exercise-Induced Myocardial Ischemia Through a Novel Mechanism of Action," <i>Circulation</i> , 1993, pp. 502-508, Vol. 88(2).			
	26	GAUBERT, Yves, "Clinical Experience with a New Antispasmodic," <i>Journal De Medicine De Bordeaux</i> , May 1967, pp. 772-776, Vol. 5.			
	27	GOTTLIEB, S.S., <i>et al.</i> , "BG9719 (CVT-124), an A ₁ Adenosine Receptor antagonist, Protects Against the Decline in Renal Function Observed with Diuretic Therapy," <i>Journal of American Heart Association</i> , 2002, pp. 1348-1353.			
	28	MARONE, G., <i>et al.</i> , "Adenosine Receptors on Human Leukocytes IV. Characterization of an A ₁ /R ₄ Receptor," <i>Int. J. Clin. Lab. Res.</i> , 1992, pp. 235242, Vol. 22.			
	29	MARONE, G., <i>et al.</i> , "Adenosine Receptors on Human Inflammatory Cells ¹ ," <i>Int. Archs Allergy appl. Immun.</i> , 1985, pp. 259-263, Vol. 77.			
MB	30	MAYNE, M., <i>et al.</i> , "Dysregulation of Adenosine A ₁ Receptor-Mediated Cytokine Expression in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients," <i>American Neurological Association</i> , 1999, pp. 633-639.			

Examiner Signature	/Mark L. Berch	Date Considered	07/13/2006
--------------------	----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/780,296		
		Filing Date	February 17, 2004		
		First Named Inventor	Wilson		
		Group Art Unit	1624		
		Examiner Name	M. Berch		
Sheet	3	of	3	Attorney Docket Number	049542/283879

U. S. PATENT DOCUMENTS			
MB	31	NEELY, C.F. <i>et al.</i> , "A ₁ Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Lung," <i>American Physiological Society</i> , 1995, pp. L1036-L1046.	
	32	NEELY, C.F. <i>et al.</i> , "A ₁ Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart," <i>American heart Association, Inc.</i> , 1996, pp. II-376-II-380.	
	33	NEELY, C.F. <i>et al.</i> , "A ₁ Adenosine Receptor Antagonists Block Endotoxin-Induced Lung Injury," <i>American Physiological Society</i> , 1997, pp. L353-L361.	
	34	MCCOY, D.E., <i>et al.</i> , "Identification and Function of A ₁ Adenosine Receptors in Normal and Cystic Fibrosis Human Airway Epithelial Cells," <i>American Physiological Society</i> , 1995, pp. C1520-C1527.	
	35	OBIEFUNA, P.C.M., <i>et al.</i> , "A Novel A ₁ Adenosine Receptor Antagonist, L-97-1 [3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-[2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl]-1-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma," <i>The Journal of Pharmacology and</i>	
	36	PANTHER, E., <i>et al.</i> , "Expression and Function of Adenosine Receptors in Human Dendritic Cells," <i>The FASEB Journal</i> , 2001, pp. 1963-1970, Vol. 15.	
	37	SALMON, J.E., <i>et al.</i> , "Human Mononuclear Phagocytes Express Adenosine A ₁ Receptors," <i>The Journal of Immunology</i> , 1993, pp. 2775-2785.	
	38	SANTOS, J.M., <i>et al.</i> "Clinical Experimentation with AC 3810 (Trentadil)," <i>Publicado en la Revista Medicina</i> , August 1964, Vol. 8.	
	39	SATOH, A., <i>et al.</i> , "Activation of Adenosine A ₁ -Receptor Pathway Induces Edema Formation in the Pancreas of Rats," <i>American Gastroenterological Association</i> , 2000, pp. 829-836, Vol. 119.	
	40	VARANI, K., <i>et al.</i> , "Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease," <i>Am J. Respir Crit Care Med</i> , 2005, pp. 398-406, Vol. 173.	
	41	WEISBERG, S.P., <i>et al.</i> , "Adenosine Receptor Antagonists Inhibit the Development of Morphine Sensitization in the C57BL/6 Mouse," <i>Neuroscience Letters</i> , 1999, pp. 89-92.	
MB	42	WILSON, C.N., <i>et al.</i> , "Lipopolysaccharide Binds to and Activates A ₁ Adenosine Receptors on human Pulmonary Artery Endothelial Cells," <i>Journal of Endotoxin Research</i> , 2002, pp. 1-9, Vol. 8.	

RTA01/2194750v1

Examiner Signature	/Mark L. Berch/	Date Considered	07/13/2006
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.